Akebia Therapeutics Inc AKBA

Operating internationally, Akebia Therapeutics is a fully integrated biopharmaceutical company. It works to develop and commercialise medications for the treatment of complications related to kidney disease. As of November 2020, the company has one commercially available medicine available within the US (Auryxia) and another medicine in global phase III development (Vadadustat). Founded in 2007, the company has its headquarters in Cambridge, Massachusetts.

The company's stock is available on the NASDAQ GS stock market using the AKBA ticker. In November 2020, this stock was trading at $3.39. The AKBA share price ranged from a 52-week high of $13.71 in both April 2020 and June 2020 before dropping to a 52-week low of $2.09 in September 2020. As of November 2020, this stock provided a -36.28% one-year return.

Akebia Therapeutics' lead product candidate, Vadudustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). The drug is intended to be used to treat anaemia due to chronic kidney disease. This candidate is in phase III clinical development. It has been approved for use within Japan for adult patients, including both dialysis-dependent and non-dialysis dependent patients.

For more information on AKBA stock and to keep up with the latest developments, make it an entry on your eToro watchlist.